Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 4Colorectal Neoplasms 3Neoplasms 2Neoplasm Metastasis 1Melanoma 1Liver Neoplasms 1Gastro-enteropancreatic neuroendocrine tumor 1Endometrial Neoplasms 1Digestive System Neoplasms 1Desmoid Tumors 1Adrenocortical Carcinoma 1

Interventions

durvalumab 13Bevacizumab 11Nivolumab 10tremelimumab 7pembrolizumab 6lenvatinib 6fludarabine 6Cyclophosphamide 6atezolizumab 4Radiosurgery 4Cisplatin 4toripalimab 3relatlimab 3Magnetic Resonance Imaging 3Ipilimumab 3Gemcitabine 3X-Rays 2Standard of Care 2Sorafenib 2Riluzole 2Radiotherapy 2Photons 2Patient Navigation 2Lidocaine 2Hepatectomy 2Dexamethasone 2Biopsy 2trastuzumab deruxtecan 1tocilizumab 1tislelizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Liver Neoplasms × E-7386 × 1 year × Clear all
NCT04008797 2026-03-24

A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor

Eisai Inc.

Phase 1/2 Active not recruiting
301 enrolled
GastrointestinalGynecologic

Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡